Sign up
Pharma Capital

CytoDyn brings on senior science advisor to develop leronlimab to treat HIV PrEP

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive Investors the late stage biotechnology company is tapping industry veteran Dr Jonah Sacha as the company’s senior science advisor.

Dr Pourhassan says Dr Sacha, who has not been given an equity stake in the company, will lead the development of the company’s flagship leronlimab (PRO 140) drug as a potential therapy for HIV pre-exposure prophylaxis (PrEP) and cure for HIV.

 

View full CYDY profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.